Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 24, 2018. The report details a significant regulatory milestone for GSK's respiratory portfolio in collaboration with Innoviva, Inc., specifically regarding the US Food and Drug Administration (FDA) approval of an expanded indication for Trelegy Ellipta.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a current report focused on a regulatory announcement rather than a financial results release.
Material Changes
- Expanded FDA Indication: The FDA approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol). It is now indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
- Exacerbation Reduction: The new label includes an indication to reduce exacerbations of COPD in patients with a history of exacerbations, broadening the eligible patient population beyond the initial September 2017 approval.
- Labeling Update: The boxed warning previously present in the Trelegy Ellipta prescribing information has been removed, aligning with recent updates to the inhaled corticosteroid/long-acting beta 2-adrenergic agonist (ICS/LABA) class approved in December 2017.
Guidance, Outlook, and Management Commentary
Dr. Hal Barron, GSK's Chief Scientific Officer, stated that the expanded indication was enabled by robust data from the landmark IMPACT study, which demonstrated Trelegy Ellipta's superiority over dual therapies (Relvar/Breo Ellipta and Anoro Ellipta) on multiple endpoints, including exacerbation reduction and lung function improvement. Management indicated they will continue to analyze IMPACT data to further demonstrate the medicine's value.
Regulatory Outlook: A type II variation to support an expanded label in Europe was submitted to the European Medicines Agency (EMA) in February 2018 and remains under review. Regulatory applications are also pending in other countries.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks described in GSK's 2017 Form 20-F and Innoviva's 2017 Form 10-K. Important Safety Information highlights risks including pneumonia, adrenal suppression, and cardiovascular disorders.
Investor Verification Checklist
- Verify the commercial impact of the expanded US indication on Trelegy Ellipta sales projections.
- Monitor the status of the European Medicines Agency (EMA) review for the expanded label submitted in February 2018.
- Review the full IMPACT study data published in the New England Journal of Medicine to assess long-term efficacy and safety profiles.
- Confirm the royalty revenue structure between GSK and Innoviva regarding Trelegy Ellipta, noting Innoviva retains a 15% economic interest in future payments.
- Assess the competitive landscape following the removal of the boxed warning and the broadening of the patient population eligible for triple therapy.